Archive for July 1st, 2009

New science review examines multiple health benefits of dairy foods

In a supplement to the current issue of the Journal of the American College of Nutrition, several prominent nutrition researchers weigh in on an updated review of the health benefits of consuming dairy foods. This supplement further contributes to the well-established evidence that consuming the recommended servings of dairy foods each day is a convenient and affordable way to get several key nutrients that many Americans do not consume enough.

More: continued here

Wednesday, July 1st, 2009

Cell transplantation and cardiac repair

Two separate studies published in the current issue of Cell Transplantation into cardiac repair by cell transplantation have found, respectively, that the best way to deliver autologous bone-marrow mononuclear cells to the heart following a myocardial infarction was via the anterograde intracoronary vein and that bone marrow cell transplants for limb ischemia induced angiogenesis in patients failing therapy and facing amputation. The first study found higher cell retention; the second demonstrated an alternative to amputation.

More: continued here

Wednesday, July 1st, 2009

Researchers testing virus-gene therapy combination against melanoma

Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body’s immune defenses against the disease.

More: continued here

Wednesday, July 1st, 2009

Astronomer’s new guide to the galaxy: Largest map of cold dust revealed

Astronomers have unveiled an unprecedented new atlas of the inner regions of the Milky Way, our home galaxy, peppered with thousands of previously undiscovered dense knots of cold cosmic dust — the potential birthplaces of new stars. Made using observations from the APEX telescope in Chile, this survey is the largest map of cold dust so far, and will prove an invaluable map for observations made with the forthcoming ALMA telescope, as well as the recently launched ESA Herschel space telescope.

More: continued here

Wednesday, July 1st, 2009

Newly appreciated membrane estrogen receptor important therapeutic target for…

New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer.

More: continued here

Wednesday, July 1st, 2009

Both good/bad movie characters who smoke influence teens to do the same

Dartmouth researchers have determined that movie characters who smoke, regardless of whether they are “good guys” or “bad guys,” influence teens to try smoking.

More: continued here

Wednesday, July 1st, 2009

Unexpectedly long-range effects in advanced magnetic devices

A tiny grid pattern has led materials scientists at NIST and the Institute of Solid State Physics in Russia to an unexpected finding — the surprisingly strong and long-range effects of certain electromagnetic nanostructures used in data storage.

More: continued here

Wednesday, July 1st, 2009

NIST develops novel ion trap for sensing force and light

A novel ion trap demonstrated at NIST could usher in a new generation of applications, because the device holds promise as a stylus for sensing very small forces or for an interface for efficient transfer of individual light particles for quantum communications.

More: continued here

Wednesday, July 1st, 2009

ADA releases updated position paper on vegetarian diets

The American Dietetic Association has released an updated position paper on vegetarian diets that concludes such diets, if well-planned, are healthful and nutritious for adults, infants, children and adolescents and can help prevent and treat chronic diseases including heart disease, cancer, obesity and diabetes.

More: continued here

Wednesday, July 1st, 2009

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

Shire announced results from a Phase 3b study that found VYVANSE (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment in adults with attention deficit hyperactivity disorder. VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented at the New Clinical Drug Evaluation Unit meeting. VYVANSE is approved by the FDA for ADHD in children aged 6 to 12 years and adults with ADHD.

More: continued here

Wednesday, July 1st, 2009